Multiplex Microsphere Assay for Zika Antibody Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Zika virus antibodies are hindered by cross-reactivity with other flaviviruses, leading to inaccurate and time-consuming diagnostic results, particularly due to the similarities in disease symptoms and antibody responses between Zika and other flaviviruses like dengue.
Innovation Solution
A method involving microspheres conjugated with specific Zika virus peptides (NS1, NS5, and envelope protein) is used to detect anti-Zika antibodies, allowing for differentiation from antibodies to other flaviviruses by utilizing a multiplex immunoassay that measures IgG and IgM responses, thereby improving diagnostic accuracy and speed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional IgM-capture ELISA is used for Zika virus detection, then the diagnostic window is extended, but cross-reactivity with other flaviviruses leads to false positives and reduced accuracy
Solution Approach 1:
The patent segments the detection process by using multiple separate microsphere sets, each conjugated to a specific flavivirus antigen (Zika, dengue, yellow fever, Japanese encephalitis). This allows simultaneous detection of antibodies against different flaviviruses in a single assay, resolving cross-reactivity issues by physically separating the detection of each virus-specific antibody population.
Solution Approach 2:
Each microsphere set is locally optimized with specific fluorescent properties and antigen conjugation. The microspheres are differentiated by fluorescent intensity and color, allowing local identification of which virus-specific antibodies are present. This local quality differentiation enables precise attribution of antibody responses to specific viruses.
2Measurement precision
If PRNT is used for confirmation of Zika virus infection, then specificity is improved, but the process becomes time-consuming and labor-intensive
Solution Approach 1:
The patent replaces the mechanical, labor-intensive PRNT process with an automated immunoassay using fluorescently-labeled microspheres. The detection is performed using a flow cytometer or similar automated instrument, eliminating the need for manual plaque reduction assays while maintaining high specificity through fluorescent signal detection.
Solution Approach 2:
The patent changes the detection parameter from measuring viral plaque reduction (PRNT) to measuring fluorescent signal intensity from antibody-microsphere complexes. This parameter change enables high-throughput automated detection while maintaining the ability to distinguish specific antibody responses, thereby improving both productivity and specificity.
3Measurement precision
If multiple flavivirus antigens are tested separately to differentiate infections, then diagnostic accuracy is improved, but the complexity and time required for testing increases
Solution Approach 1:
The patent merges the detection of multiple flavivirus-specific antibodies into a single multiplex assay. Different microsphere sets conjugated to different flavivirus antigens are combined in one reaction well, allowing simultaneous detection of antibodies against Zika, dengue, yellow fever, and Japanese encephalitis viruses. The results are differentiated by fluorescent properties of the microspheres.
Solution Approach 2:
The microsphere-based platform serves multiple functions: it detects antibodies against different flaviviruses, differentiates between them using fluorescent properties, and provides quantitative measurement of antibody levels. This universal platform replaces multiple separate assays with a single multi-functional test system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and sensitivity of Zika virus antibody detection, reducing false positives and allowing for precise differentiation from other flavivirus infections, thereby improving the accuracy of diagnosing current or past Zika infections.
Implementation Method 1
contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide... to permit binding of anti-ZIKV antibodies present in the sample to said microspheres
Data Source
AI summary
Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension. Also provided is a kit containing reagents and compositions for performing the foregoing method.